• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[123I-碘苯甲酰胺在帕金森病和帕金森叠加综合征鉴别诊断中的应用经验]

[Experience with 123I-Iodobenzamide in the differential diagnosis of Parkinson's disease and Parkinson-plus disease].

作者信息

Paniagua Correa C, García Alonso P, Balsa Bretón M A, Mariana Monguía A, Penín González F J, Pey Illera C

机构信息

Servicio de Medicina Nuclear, Hospital Universitario de Getafe, Getafe, Madrid, España.

出版信息

Rev Esp Med Nucl. 2010 Mar-Apr;29(2):57-62. doi: 10.1016/j.remn.2009.12.008. Epub 2010 Feb 4.

DOI:10.1016/j.remn.2009.12.008
PMID:20133020
Abstract

OBJECTIVE

To perform a descriptive analysis of the clinical and diagnostic implications of (123)I-IBZM SPECT in the patients studied in our center for movement disorders suggestive of Parkinson-Plus Disease (PP).

SUBJECTS AND METHODS

(123)I-IBZM SPECT was performed in 46 patients referred from the movement disorders consultation due to suspicion of PP. According to their symptoms, they were distributed into 3 groups: 35 patients had atypical symptoms (AS) for Parkinson's Disease, 2 showed no response to standard therapy (NR) and 9 presented both factors (AS, NR). The results of SPECT were only assessed qualitatively.

RESULTS

The (123)I-IBZM supported the diagnosis of PP in 15(42.9%) out of the 35 patients with AS. The (123)I-IBZM was pathological in one of the two NR patients. Regarding the third group of patients (AS+NR), the (123)I-IBZM was pathological in 6 cases (66.7%). In 95.7% of our sample (44 patients), AS with or without NR was the main factor leading to suspicion of PP and the (123)I-IBZM was altered in only 47.7% (22 patients). Of these 22 cases, the final diagnosis was PP (with high positive predictive value) in 20(91%).

CONCLUSION

The study with (123)I-IBZM is useful in the clinical practice because it provides objective diagnostic information with implications for the treatment and prognosis of patients with suspicion of PP.

摘要

目的

对我院针对疑似帕金森叠加综合征(PP)的运动障碍患者进行的(123)I-碘苄胍单光子发射计算机断层扫描(SPECT)的临床及诊断意义进行描述性分析。

对象与方法

对46例因疑似PP从运动障碍门诊转诊而来的患者进行了(123)I-碘苄胍SPECT检查。根据症状,将他们分为3组:35例患者有帕金森病的非典型症状(AS),2例对标准治疗无反应(NR),9例同时具备这两个因素(AS、NR)。SPECT结果仅进行定性评估。

结果

在35例有AS的患者中,(123)I-碘苄胍支持PP诊断的有15例(42.9%)。在2例NR患者中,有1例(123)I-碘苄胍结果呈病理性。对于第三组患者(AS+NR),(123)I-碘苄胍有6例(66.7%)呈病理性。在我们的样本中,95.7%(44例患者)的AS伴或不伴NR是导致疑似PP的主要因素,而(123)I-碘苄胍结果异常的仅占47.7%(22例患者)。在这22例中,最终诊断为PP(阳性预测值高)的有20例(91%)。

结论

(123)I-碘苄胍研究在临床实践中有用,因为它能提供客观的诊断信息,对疑似PP患者的治疗和预后有重要意义。

相似文献

1
[Experience with 123I-Iodobenzamide in the differential diagnosis of Parkinson's disease and Parkinson-plus disease].[123I-碘苯甲酰胺在帕金森病和帕金森叠加综合征鉴别诊断中的应用经验]
Rev Esp Med Nucl. 2010 Mar-Apr;29(2):57-62. doi: 10.1016/j.remn.2009.12.008. Epub 2010 Feb 4.
2
Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes.帕金森叠加综合征中多巴胺 D2 受体结合位点的丧失。
J Nucl Med. 1998 Jun;39(6):954-60.
3
Quantitative analysis of striatal dopamine D2 receptors with 123 I-iodolisuride SPECT in degenerative extrapyramidal diseases.用¹²³I-碘利舒脲单光子发射计算机断层扫描对退行性锥体外系疾病纹状体多巴胺D2受体进行定量分析。
Nucl Med Commun. 2001 Nov;22(11):1207-14. doi: 10.1097/00006231-200111000-00007.
4
[SPECT with 123I-IBZM: utility in differential diagnosis of degenerative Parkinsonisms and establishment of quantification method].[用123I-碘苄胍单光子发射计算机断层扫描:在退行性帕金森综合征鉴别诊断中的应用及定量方法的建立]
Rev Esp Med Nucl. 2005 Jul-Aug;24(4):234-43. doi: 10.1157/13076641.
5
[Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].[利用123I-碘苄酰胺(IBZM)进行多巴胺(D2)受体单光子发射计算机断层显像在帕金森综合征诊断中的应用]
Radiologe. 1995 Nov;35(11):838-43.
6
[Initial experiences with 123-Iodine-IBZM neuroreceptor scintigraphy in extrapyramidal disorders].[123-碘-IBZM神经受体闪烁显像术在外锥体外系疾病中的初步经验]
Orv Hetil. 2000 May 14;141(20):1073-7.
7
[The differential diagnosis of Parkinson diseases--123I-IBZM-SPECT vs. the apomorphine test].[帕金森病的鉴别诊断——123I-IBZM单光子发射计算机断层扫描与阿扑吗啡试验对比]
Rofo. 1993 Jul;159(1):86-90. doi: 10.1055/s-2008-1032726.
8
Cortical and subcortical patterns of I-123 iodobenzamide SPECT in striatal D(2) receptor parkinsonisms.纹状体 D(2) 受体帕金森病患者 I-123 碘苯酰胺 SPECT 的皮质和皮质下模式。
Clin Nucl Med. 2010 Apr;35(4):228-33. doi: 10.1097/RLU.0b013e3181d18cb3.
9
Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT.阿扑吗啡试验中的临床反应与由123I IBZM单光子发射计算机断层扫描(SPECT)所显示的D2受体状态的相关性。
Mov Disord. 1993 Oct;8(4):453-8. doi: 10.1002/mds.870080406.
10
123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism.83例初发性帕金森病患者的123I-碘苯甲酰胺单光子发射计算机断层扫描
Neurology. 1993 Dec;43(12 Suppl 6):S17-20.